Benlysta 400 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FM49D
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,763
Award facts
- Contract value 100% obligated
- $22,763.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $22,763.40 to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Benlysta 400 mg vials, with an ultimate completion date of February 20, 2026. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open and competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at up to $999,999,999.00 and extending through December 2026.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving critical federal medical procurement needs for military and veteran healthcare systems. The company's extensive contract portfolio demonstrates its capability to supply a diverse range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Benlysta (belimumab) is a monoclonal antibody used primarily in the treatment of systemic lupus erythematosus, reflecting the breadth of specialized therapeutics delivered through DLA's pharmaceutical supply chain to support military healthcare programs worldwide.
Quick answers
Who was awarded contract SPE2DR26FM49D?
SPE2DR26FM49D was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FM49D worth?
The government has obligated $22,763 on SPE2DR26FM49D.
Is contract SPE2DR26FM49D an order under another contract?
Yes. SPE2DR26FM49D is a delivery order under SPE2DR25D2007, an indefinite delivery contract.
Was contract SPE2DR26FM49D competed?
The extent of competition for SPE2DR26FM49D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award